Skip to main content

Advertisement

Log in

The economic burden of the care and treatment for people with Alzheimer’s disease: the outlook for the Czech Republic

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

The aim of this paper is to specify the cost of treatment and care for people with Alzheimer’s disease (AD) in the Czech Republic and also with a view to the future. Data availability is evaluated as well as the quality of cost comparison with other developed countries. Data for the Czech Republic will include data from the health insurance company regarding medicines and treatment, as well as a selected home caring for people with dementia and, ultimately, the Social Security Administration. The basic methods include an analysis of data from publicly available sources, direct interviews with the representatives of nursing homes caring for people with dementia and the representative of the Social Security Administration of the Czech Republic. Items will be specified within the category of direct costs. For the study, the indirect costs related to the loss of patient as well as caring person productivity are not considered. Costs for treatment and care are based from the data on 4162 patients, the costs of a bed from data on 391 beds in homes for the elderly. The average annual cost per patient with AD in the Czech Republic was calculated and came to the amount of 12,783 EUR. These items include outpatient care, inpatient care in a medical facility, inpatient care in homes and medications. In terms of share of these items on the direct costs, the largest item are services provided by special homes which contributes to the direct costs by 94 %, medications create 1 % and treatment (both outpatient and inpatient) 5 %. In the case of home care the total costs are lower at 4698 EUR. The Czech Republic as well as other developed countries are faced with the problem of unified accounting cost of people suffering from Alzheimer’s disease. This then causes the calculation of the economic burden to be very difficult and indicative values.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Source: own processing based on data from [2]

Similar content being viewed by others

References

  1. Pidrman V (2007) Dementia. Grada Publishing, Prague

    Google Scholar 

  2. Alzheimer´s Disease International (2016) http://www.alz.co.uk/. Accessed 26 April 2016

  3. Czech Alzheimer Society (CAS) (2015) http://www.alzheimer.cz/. Accessed 26 April 2016

  4. Maresova P, Mohleska H, Kuca K (2015) Social and family load of Alzheimer’s disease. Appl Econ. doi:10.1080/00036846.2015.1111986

    Google Scholar 

  5. Mohelska H, Maresova P, Valis M, Kuca K (2015) Alzheimer’s disease and its treatment costs: Case Study in the Czech Republic. Neuropsychiatr Dis Treat 11:2349–2354. doi:10.2147/NDT.S87503

    PubMed  PubMed Central  Google Scholar 

  6. Maresova P, Mohelska H, Dolejs J, Kuca K (2015) Socio-economic aspects of Alzheimer’s disease. Curr Alzheimer Res 12(9):903–911

    Article  CAS  PubMed  Google Scholar 

  7. Allegri RF, Butman J, Arizaga RL et al (2007) Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina. Int Psychogeriatr 19:705–718

    Article  PubMed  Google Scholar 

  8. Wang G, Cheng Q, Zhang S et al (2008) Economic impact of de-mentia in developing countries: an evaluation of Alzheimer-type dementia in Shanghai, China. J Alzheimer Dis 15:109–115

    Google Scholar 

  9. Mesterton et al (2010) Cross sectional observational study on the societal costs of Alzheimer’s disease. Curr Alzheimer Res 7(4):358–367

    Article  CAS  PubMed  Google Scholar 

  10. Lamb HM, Goa KL (2001) Rivastigmine. A pharmacoeconomic re-view of its use in Alzheimer’s disease. Pharmacoeconomics 19:303–318

    Article  CAS  PubMed  Google Scholar 

  11. Wimo A (2004) Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer’s disease: a review with methodologi-cal considerations. Drugs Aging 21:279–295

    Article  CAS  PubMed  Google Scholar 

  12. Herrmann N, Lanctôt KL, Sambrook R et al (2006) The contribu-tion of neuropsychiatric symptoms to the cost of dementia care. Int J Geriatr Psychiatry 21:972–976

    Article  PubMed  Google Scholar 

  13. Castro D, Dillon C, Machnicki G, Allegri R (2010) The economic cost of Alzheimer’s disease: family or public-health burden? Dement Neuropsychol 4:262–267

    Article  Google Scholar 

  14. Rice DP, Fox PJ, Max W et al (1993) The economic burden of Alzheimer’s disease care. Health Aff (Millwood) 12:164–176

    Article  CAS  Google Scholar 

  15. Dodel et al (2015) Determinants of societal costs in Alzheimer’s disease: GERAS study baseline results. Alzheimer’s Dement 11(2015):933–945

    Article  Google Scholar 

  16. Bloom et al (2003) Cost of illness of Alzheimer’s disease: How useful are current estimates? The Gerontologist 43(2):158–164

    Article  PubMed  Google Scholar 

  17. Drummond MF, O´Brien BJ (2005) Methods for the economic evaluation of health care programmes. Oxford University, New York

    Google Scholar 

  18. The State Institute for Drug Control (SUKL) (2012). Evaluation of the development of distribution selected group of medicines. State Institute for Drug Control. http://www.sukl.cz/hodnoceni-vyvoje-distribuce-vybrane-skupiny-lecivych-9. Accessed 26 April 2016

  19. Czech Statisical Office (CSO) (2014) Ageing population according to the results of the CSO projection. http://www.demografie.info/?cz_detail_clanku&artclID. Accessed 26 April 2016

  20. Gervès Ch, Chauvin P, Bellanger MM (2014) Evaluation of full costs of care for patients with Alzheimer’s disease in France: the predominant role of informal care. Health Policy 116(1):114–122

    Article  PubMed  Google Scholar 

  21. Schwarzkopf L, Menn P, Kunz S et al (2011) Costs of care for dementia patients in community setting: an analysis for mild and moderate disease stage. Value Health 14(6):827–835. doi:10.1016/j.jval.2011.04.005

    Article  PubMed  Google Scholar 

  22. Travnickova J(2013). Economics and management in health care: 3rd edition of Proceedings of the student scientific conference organized by the Department of Biomedical Technology: Kladno, p 205–212

Download references

Acknowledgments

This study was supported by the project Excellence 2015 (University of Hradec Kralove, Faculty of Informatics and Management) and Economics and Managerial aspects of processes in Biomedicine.

Author contribution statement

PM and VZ equally contributed to the drafting, analyses and final version of the whole manuscript. All authors read and approved the final manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Petra Marešová.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests to declare.

Availability of data and materials

All the data and materials in this manuscript will be shared.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marešová, P., Zahálková, V. The economic burden of the care and treatment for people with Alzheimer’s disease: the outlook for the Czech Republic. Neurol Sci 37, 1917–1922 (2016). https://doi.org/10.1007/s10072-016-2679-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-016-2679-6

Keywords

Navigation